The primary purpose of this study is to assess whether Acelarin (NUC-1031) is superior to
gemcitabine in terms of overall survival for treatment of patients with metastatic pancreatic
carcinoma. In addition disease progression, quality of life and comparative safety will be
evaluated. Secondary objectives are to compare between the two treatment groups the
following:
- Progression Free Survival (PFS)
- Radiological Response and disease control rate
- Toxicity and safety
- Quality of Life
Additional, exploratory objectives are to discover and validate possible biomarkers to
predict additional benefit of Acelarin (NUC-1031) over gemcitabine alone.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
The Clatterbridge Cancer Centre NHS Foundation Trust